vMember of the German Center for Lung Research and Cardiopulmonary Institute, and Agaplesion Lung Clinic Waldhof-Elgershausen, Greifenstein, Germany Study group members are listed in appendix.

† Key Laboratory of Colloid and Interface Science, Beijing National Laboratory for Molecular Sciences (BNLMS), Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, People’s Republic of ...

The group emphasized balancing survival benefits with toxicity and selecting therapies with distinct mechanisms of action instead of rechallenging patients with similar therapies. What are the goals ...

Avalyn’s poster presentation at EULAR 2025 will include the Phase 2b study design of AP01 (inhaled pirfenidone) in various forms of progressive pulmonary fibrosis (PPF), including autoimmune ILDs.

Data from phase II studies also suggest that pirfenidone, which has a different—yet largely unknown—mechanism of action, may also have activity in other fibrosing ILDs with a progressive phenotype, in ...

With the rapid advancement of bioinformatics and systems biology, network pharmacology (14), as a powerful means, has been widely applied to reveal the complex mechanisms of drug action. Network ...

Nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B) with antifibrotic and immunomodulatory effects, a mechanism different than approved antifibrotic treatments pirfenidone ...

State Key Laboratory of Biobased Material and Green Papermaking, College of Food Science and Engineering, Qilu University of Technology, Shandong Academy of Science, Jinan 250353, China Department of ...